NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Forecast, Price & News $4.02 -0.12 (-2.90%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$3.94▼$4.3650-Day Range$2.12▼$4.4752-Week Range$1.81▼$13.73Volume531,998 shsAverage Volume1.87 million shsMarket Capitalization$160.91 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Oramed Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside372.6% Upside$19.00 Price TargetShort InterestHealthy1.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 7 Articles This WeekInsider TradingAcquiring Shares$293,240 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector479th out of 983 stocksPharmaceutical Preparations Industry231st out of 486 stocks 3.0 Analyst's Opinion Consensus RatingOramed Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Oramed Pharmaceuticals has a forecasted upside of 372.6% from its current price of $4.02.Amount of Analyst CoverageOramed Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.21% of the outstanding shares of Oramed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 6.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOramed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORMP. Previous Next 2.7 News and Social Media Coverage News SentimentOramed Pharmaceuticals has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -89% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $293,240.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Oramed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 10.08% of the stock of Oramed Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oramed Pharmaceuticals (NASDAQ:ORMP) StockOramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.Read More Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORMP Stock News HeadlinesJune 2, 2023 | americanbankingnews.comBrokers Issue Forecasts for Oramed Pharmaceuticals Inc.'s Q2 2023 Earnings (NASDAQ:ORMP)May 30, 2023 | finance.yahoo.comORMP: Advancing Development Efforts in ChinaJune 4, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 27, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Increased by AnalystMay 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Oramed Pharm (ORMP)May 22, 2023 | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) Now Covered by Analysts at StockNews.comMay 18, 2023 | msn.comCanaccord Genuity Maintains Oramed Pharmaceuticals (ORMP) Hold RecommendationMay 18, 2023 | finance.yahoo.comOramed to Present at Novel Therapies for Type 2 Diabetes & Obesity SummitJune 4, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 16, 2023 | msn.comOramed Surges on New Diabetes TreatmentMay 15, 2023 | msn.comWhy Oramed Pharmaceuticals Shares Are Trading Higher TodayMay 15, 2023 | finance.yahoo.comOramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in ChinaMay 3, 2023 | msn.comInvesting millions, Ben Shapiro joins board of Oramed PharmaceuticalsMay 2, 2023 | marketwatch.com8-K: ORAMED PHARMACEUTICALS INC.May 2, 2023 | finance.yahoo.comConservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug CompanyMay 1, 2023 | finance.yahoo.comOramed Appoints Ben Shapiro to its Board of DirectorsApril 19, 2023 | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to "Hold" by StockNews.comApril 12, 2023 | americanbankingnews.comStockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to SellApril 5, 2023 | money.usnews.comOramed Pharmaceuticals, IncMarch 31, 2023 | americanbankingnews.comFinancial Review: Oramed Pharmaceuticals (NASDAQ:ORMP) & Pharming Group (NASDAQ:PHAR)March 27, 2023 | finance.yahoo.comThe past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitableMarch 26, 2023 | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below Two Hundred Day Moving Average of $5.97March 16, 2023 | benzinga.comOramed Pharmaceuticals Chief Scientific Officer Sold $200K In Company StockMarch 16, 2023 | benzinga.comDirector of Oramed Pharmaceuticals Makes $141K BuyMarch 13, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Oramed Pharm (ORMP)February 16, 2023 | finance.yahoo.comOramed Pharmaceuticals Inc. (ORMP.TA)February 9, 2023 | finance.yahoo.comOramed Pharmaceuticals Issues Shareholder UpdateSee More Headlines ORMP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORMP Company Calendar Last Earnings3/06/2023Today6/03/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORMP CUSIPN/A CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees12Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+372.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,560,000.00 Net Margins-1,093.27% Pretax Margin-1,130.85% Return on Equity-19.46% Return on Assets-18.24% Debt Debt-to-Equity RatioN/A Current Ratio31.21 Quick Ratio31.21 Sales & Book Value Annual Sales$2.70 million Price / Sales59.60 Cash FlowN/A Price / Cash FlowN/A Book Value$3.75 per share Price / Book1.07Miscellaneous Outstanding Shares40,030,000Free Float37,265,000Market Cap$160.92 million OptionableOptionable Beta1.78 Key ExecutivesNadav KidronPresident, Chief Executive Officer & DirectorJoshua HexterChief Operating & Business OfficerMiriam KidronDirector & Chief Scientific OfficerMichael RabinowitzChief Commercial OfficerZach HerschfusHead-Investor RelationsKey CompetitorsXBiotechNASDAQ:XBITProPhase LabsNASDAQ:PRPHNanobiotixNASDAQ:NBTXDURECTNASDAQ:DRRXLongboard PharmaceuticalsNASDAQ:LBPHView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Sold 230,495 shares on 5/18/2023Ownership: 0.435%Susquehanna International Group Ltd.Bought 113,526 shares on 5/16/2023Ownership: 0.284%State Street CorpBought 2,873 shares on 5/16/2023Ownership: 0.135%Jane Street Group LLCSold 62,188 shares on 5/16/2023Ownership: 0.102%Apollon Wealth Management LLCBought 20,000 shares on 5/16/2023Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions ORMP Stock - Frequently Asked Questions Should I buy or sell Oramed Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ORMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORMP, but not buy additional shares or sell existing shares. View ORMP analyst ratings or view top-rated stocks. What is Oramed Pharmaceuticals' stock price forecast for 2023? 3 brokers have issued 12 month price objectives for Oramed Pharmaceuticals' shares. Their ORMP share price forecasts range from $3.00 to $35.00. On average, they anticipate the company's share price to reach $19.00 in the next year. This suggests a possible upside of 372.6% from the stock's current price. View analysts price targets for ORMP or view top-rated stocks among Wall Street analysts. How have ORMP shares performed in 2023? Oramed Pharmaceuticals' stock was trading at $12.03 at the start of the year. Since then, ORMP stock has decreased by 66.6% and is now trading at $4.02. View the best growth stocks for 2023 here. When is Oramed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our ORMP earnings forecast. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its earnings results on Monday, March, 6th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.22). The biotechnology company earned $0.68 million during the quarter, compared to analysts' expectations of $0.75 million. Oramed Pharmaceuticals had a negative trailing twelve-month return on equity of 19.46% and a negative net margin of 1,093.27%. What ETFs hold Oramed Pharmaceuticals' stock? ETFs with the largest weight of Oramed Pharmaceuticals (NASDAQ:ORMP) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and BlueStar Israel Technology ETF (ITEQ) and What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN). What is Oramed Pharmaceuticals' stock symbol? Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP." Who are Oramed Pharmaceuticals' major shareholders? Oramed Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (3.41%), Two Sigma Investments LP (1.26%), Two Sigma Advisers LP (1.11%), JPMorgan Chase & Co. (0.43%), XTX Topco Ltd (0.38%) and Susquehanna International Group Ltd. (0.28%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Oramed Pharmaceuticals' stock price today? One share of ORMP stock can currently be purchased for approximately $4.02. How much money does Oramed Pharmaceuticals make? Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $160.92 million and generates $2.70 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. How can I contact Oramed Pharmaceuticals? Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004. This page (NASDAQ:ORMP) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.